Deep Track Capital LP Has $25.50 Million Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)
Deep Track Capital LP Has $25.50 Million Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)
Deep Track Capital LP grew its holdings in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Rating) by 15.3% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,729,757 shares of the specialty pharmaceutical company's stock after purchasing an additional 229,757 shares during the period. KalVista Pharmaceuticals comprises 1.6% of Deep Track Capital LP's holdings, making the stock its 22nd largest holding. Deep Track Capital LP owned 7.05% of KalVista Pharmaceuticals worth $25,497,000 as of its most recent SEC filing.
据KalVista PharmPharmticals，Inc.(纳斯达克代码：KALV-GET评级)在最近提交给美国证券交易委员会的文件中称，该公司第一季度增持该公司股票15.3%。该机构投资者持有这家专业制药公司1,729,757股票，在此期间又购买了229,757股票。KalVista制药公司持有Deep Track Capital LP 1.6%的股份，使其成为其第22大持股。截至最近提交给美国证券交易委员会的文件，Deep Track Capital LP持有KalVista PharmPharmticals 7.05%的股份，价值25,497,000美元。
A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Frazier Life Sciences Management L.P. bought a new position in shares of KalVista Pharmaceuticals during the first quarter valued at $23,174,000. Laurion Capital Management LP boosted its holdings in KalVista Pharmaceuticals by 291.7% during the fourth quarter. Laurion Capital Management LP now owns 470,000 shares of the specialty pharmaceutical company's stock worth $6,218,000 after purchasing an additional 350,000 shares during the last quarter. Suvretta Capital Management LLC boosted its holdings in KalVista Pharmaceuticals by 13.2% during the fourth quarter. Suvretta Capital Management LLC now owns 1,746,300 shares of the specialty pharmaceutical company's stock worth $23,104,000 after purchasing an additional 203,016 shares during the last quarter. American Century Companies Inc. boosted its holdings in KalVista Pharmaceuticals by 27.7% during the first quarter. American Century Companies Inc. now owns 484,103 shares of the specialty pharmaceutical company's stock worth $7,136,000 after purchasing an additional 104,870 shares during the last quarter. Finally, BlackRock Inc. boosted its holdings in KalVista Pharmaceuticals by 2.6% during the first quarter. BlackRock Inc. now owns 1,544,027 shares of the specialty pharmaceutical company's stock worth $22,757,000 after purchasing an additional 39,407 shares during the last quarter.
其他一些机构投资者和对冲基金最近也改变了他们在该业务中的头寸。弗雷泽生命科学管理公司在第一季度购买了价值23,174,000美元的KalVista制药公司的新股票头寸。劳里安资本管理公司在第四季度增持了卡尔维斯塔制药公司的股份291.7%。Laurion Capital Management LP在上个季度额外购买了35万股票后，现在拥有47万股这家专业制药公司的股票，价值621.8万美元。Suvretta Capital Management LLC在第四季度将其在KalVista PharmPharmticals的持股增加了13.2%。Suvretta Capital Management LLC在上个季度额外购买了203,016股票后，现在拥有这家专业制药公司1,746,300股票，价值23,104,000美元。美国世纪公司第一季度增持的KalVista PharmPharmticals股份增加了27.7%。美国世纪公司目前持有这家专业制药公司的484,103股股票，价值7,136,000美元，该公司在上个季度又购买了104,870股。最后，贝莱德股份有限公司在第一季度增持了卡尔维斯塔制药2.6%的股份。贝莱德股份有限公司在上个季度增持了39,407股后，目前持有这家专业制药公司1,544,027股股票，价值22,757,000美元。
KalVista Pharmaceuticals Price Performance
KalVista制药公司的价格表现
NASDAQ KALV opened at $15.87 on Friday. The company's 50 day moving average is $13.87 and its 200-day moving average is $12.90. KalVista Pharmaceuticals, Inc. has a 12-month low of $8.00 and a 12-month high of $21.76.
纳斯达克KALV上周五开盘报15.87美元。该公司的50日移动均线切入位在13.87美元，200日移动均线切入位在12.90美元。KalVista PharmPharmticals，Inc.的12个月低点为8.00美元，12个月高位为21.76美元。
Analyst Ratings Changes
分析师评级发生变化
A number of research analysts have weighed in on the stock. Needham & Company LLC dropped their target price on shares of KalVista Pharmaceuticals from $42.00 to $38.00 and set a "buy" rating on the stock in a research note on Friday, July 8th. SVB Leerink dropped their target price on shares of KalVista Pharmaceuticals from $51.00 to $45.00 and set an "outperform" rating on the stock in a research note on Friday, July 8th.
一些研究分析师对该股进行了分析。Needham&Company LLC在7月8日(星期五)的一份研究报告中将KalVista制药公司的股票目标价从42.00美元下调至38.00美元，并对该股设定了“买入”评级。SVB Leerink在7月8日(星期五)的一份研究报告中将KalVista制药公司的股票目标价从51.00美元下调至45.00美元，并对该股设定了“跑赢大盘”的评级。
Insider Activity
内幕活动
In other news, CEO Thomas Andrew Crockett sold 1,797 shares of the business's stock in a transaction that occurred on Wednesday, August 17th. The shares were sold at an average price of $14.96, for a total value of $26,883.12. Following the sale, the chief executive officer now owns 112,178 shares of the company's stock, valued at $1,678,182.88. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 8.30% of the company's stock.
在其他新闻方面，首席执行官托马斯·安德鲁·克罗基特在8月17日星期三的一笔交易中出售了1,797股该公司的股票。这些股票的平均价格为14.96美元，总价值为26,883.12美元。出售后，这位首席执行官现在拥有112,178股公司股票，价值1,678,182.88美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的，可以通过美国证券交易委员会网站访问该文件。内部人士持有该公司8.30%的股份。
About KalVista Pharmaceuticals
关于KalVista制药公司
(Get Rating)
(获取评级)
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.
KalVista制药公司是一家临床阶段制药公司，发现、开发和商业化小分子蛋白酶抑制剂，用于治疗未得到满足的需求的疾病。该公司的产品组合包括针对遗传性血管水肿(HAE)和糖尿病黄斑水肿(DME)的小分子血浆激肽释放酶抑制剂；以及口服血浆激肽释放酶抑制剂。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on KalVista Pharmaceuticals (KALV)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
- 免费获取StockNews.com关于KalVista制药公司(KALV)的研究报告
- MarketBeat：回顾一周9/5-9/9
- 为网络安全股创纪录的季度做准备
- 汽车市场正在缓慢复苏，这些股票可能表现优异
- DocuSign是否即将发生重大逆转？
- 石油和天然气股票：投资可再生能源的安全途径
Receive News & Ratings for KalVista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
接受KalVista制药日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对KalVista制药公司和相关公司的最新新闻和分析师评级的每日摘要。